What is Maruzen Pharmaceuticals Co., Ltd. doing to promote renewable energy at its Miyoshi Plant?

Maruzen Pharmaceuticals Co., Ltd. has introduced renewable energy power generation via a PPA (Power Purchase Agreement) at its Miyoshi Plant, effective March 2026, by installing solar panels on the building's roof.

What is the expected annual reduction in CO2 emissions from the Miyoshi Plant's renewable energy initiative?

The initiative at the Miyoshi Plant is expected to result in an annual reduction of 250 tons of CO2 per year, by converting approximately 460,000 kWh of electricity to renewable energy.

Besides the Miyoshi Plant, where else is Maruzen Pharmaceuticals implementing renewable energy initiatives?

Maruzen Pharmaceuticals' Shin-Onomichi Plant reduces CO2 by 88 tons annually with its own solar panels, and Kui Farm reduces CO2 by 32 tons annually. They also plan to introduce PPA at their General Research Institute and transition electricity at their Tokyo Branch to renewable energy in the new fiscal year.

What is Maruzen Pharmaceuticals' overarching goal regarding greenhouse gas emissions by 2030?

Maruzen Pharmaceuticals aims for a 46% reduction in greenhouse gas emissions by 2030, compared to 2013 levels, which is a key materiality target.

When did Maruzen Pharmaceuticals Co., Ltd. establish its business and what are its main business activities?

Maruzen Pharmaceuticals Co., Ltd. was established on July 13, 1949, and its business description includes the manufacturing and sales of pharmaceuticals, various material extracts (pharmaceutical, quasi-drug, cosmetic, food, health food), food additives, food products, and health foods.

AI News NQ Analysis

Maruzen Pharmaceuticals Co., Ltd. | Introduction of PPA-based Renewable Energy Power Generation at Miyoshi Plant

NQ Score 56/100

Key facts

Maruzen Pharmaceuticals Co., Ltd. | Introduction of PPA-based Renewable Energy Power Generation at Miyoshi Plant
Maruzen Pharmaceuticals promotes CO2 reduction by introducing PPA-based renewable energy power generation at its Miyoshi Plant.
Date: Sun Mar 29 2026 16:36:22 GMT+0900 (Japan Standard Time)

Direct answer

Maruzen Pharmaceuticals promotes CO2 reduction by introducing PPA-based renewable energy power generation at its Miyoshi Plant.

Citation: Maruzen Pharmaceuticals Co., Ltd. | Introduction of PPA-based Renewable Energy Power Generation at Miyoshi Plant (Sun Mar 29 2026 16:36:22 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Sun Mar 29 2026 16:36:22 GMT+0900 (Japan Standard Time)

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is Maruzen Pharmaceuticals Co., Ltd. doing to promote renewable energy at its Miyoshi Plant?: A: Maruzen Pharmaceuticals Co., Ltd. has introduced renewable energy power generation via a PPA (Power Purchase Agreement) at its Miyoshi Plant, effective March 2026, by installing solar panels on the building's roof.
Q: What is the expected annual reduction in CO2 emissions from the Miyoshi Plant's renewable energy initiative?: A: The initiative at the Miyoshi Plant is expected to result in an annual reduction of 250 tons of CO2 per year, by converting approximately 460,000 kWh of electricity to renewable energy.
Q: Besides the Miyoshi Plant, where else is Maruzen Pharmaceuticals implementing renewable energy initiatives?: A: Maruzen Pharmaceuticals' Shin-Onomichi Plant reduces CO2 by 88 tons annually with its own solar panels, and Kui Farm reduces CO2 by 32 tons annually. They also plan to introduce PPA at their General Research Institute and transition electricity at their Tokyo Branch to renewable energy in the new fiscal year.
Q: What is Maruzen Pharmaceuticals' overarching goal regarding greenhouse gas emissions by 2030?: A: Maruzen Pharmaceuticals aims for a 46% reduction in greenhouse gas emissions by 2030, compared to 2013 levels, which is a key materiality target.
Q: When did Maruzen Pharmaceuticals Co., Ltd. establish its business and what are its main business activities?: A: Maruzen Pharmaceuticals Co., Ltd. was established on July 13, 1949, and its business description includes the manufacturing and sales of pharmaceuticals, various material extracts (pharmaceutical, quasi-drug, cosmetic, food, health food), food additives, food products, and health foods.